Video Shorts

0:44
Key Biopharma Trends That Emerged in Q3 2025
a year ago
by
Patrick Lavery

0:31
Life Science CEOs Making AI a Top Priority: Report
a year ago
by
Patrick Lavery

0:59
3 Types of Cell & Gene Therapy Products You Must Know
a year ago
by
Feliza Mirasol

0:49
A Breeze of Optimism in a Tough Biotech Climate
a year ago
by
Feliza Mirasol

0:37
How Important Are Small Biotechs in Driving Drug Development for Rare Diseases?
a year ago
by
Feliza Mirasol

1:55
Two-Minute Mysteries: BioPharm Stories - A Mysterious Low Reading
a year ago
by
Chris Spivey(+1 more)

0:33
What Potential Do Investors See in the Rare Disease Space?
a year ago
by
Feliza Mirasol

0:17
How Enzene's US Expansion Meets Continuous Manufacturing Demand
a year ago
by
Patrick Lavery

0:20
Finding the Right CDMO Partner by Localizing Manufacturing in the US
a year ago
by
Patrick Lavery

0:22
Enzene's 20-Year Vision for Innovation and Global Impact
a year ago
by
Patrick Lavery

0:33
Why the Focus from Industry on Rare Diseases?
a year ago
by
Feliza Mirasol

0:34
Junevity's Bold Move: Using siRNA to Fight Diabetes and Obesity
a year ago
by
Christopher Cole

1:22
How tRNAs Could Revolutionize Treatment for Dravet & More
a year ago
by
Christopher Cole

0:53
AI Boosts Early Disease Detection and Diagnostic Accuracy
a year ago
by
Christopher Cole

0:23
Why Onshoring Manufacturing Is a Smart Move Today
a year ago
by
Christopher Cole

0:29
From Nice to Have to Mandatory: Pharma’s Sustainability Makeover
a year ago
by
Christopher Cole

0:25
How Tailored Drug Formulations Create Patentable Innovations
a year ago
by
Christopher Cole

1:22
Operators Are the Main Source of Contamination in Pharmaceutical Manufacturing
a year ago
by
Christopher Cole
Advertisement
Advertisement
Trending on BioPharm International
1
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
2
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
5
